Overview

A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-2)

Status:
RECRUITING

Trial end date:
2028-11-13

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate the efficacy and safety of KarXT + KarX-EC in adult participants with agitation related to Alzheimer's Disease.

Phase:

PHASE3

Details

Lead Sponsor:

Bristol-Myers Squibb

Treatments:

trospium chloride
xanomeline